This bill, titled the "Maintaining Investments in New Innovation Act," proposes an amendment to Title XI of the Social Security Act to bolster protections for certain innovative pharmaceutical products. Its central aim is to extend the duration for which specific drugs are designated as "qualifying single source drugs." The legislation specifically increases this period from 7 years to 11 years for a newly defined category of advanced drug products . These products are characterized as drugs that incorporate or utilize genetically targeted technology , capable of modulating the function of a gene or its associated gene product. This amendment is intended to incentivize and safeguard investments in the research and development of these cutting-edge genetic therapies.